EPHA5, His, Human
EPHA5, His, Human

The purity of EPHA5, His, Human is greater than 95% as determined by SEC-HPLC.

EPHA5, His, Human

EPHA5, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

EPHA5, His, Human

Ephrin type-A receptor 5 (EphA5) expression was detected in all non-tumor gastric epithelia but was differentially expressed among gastric cancer samples. EphA5 is differentially expressed in gastric cancer. EphA5 may therefore be a potential therapeutic target and may have clinical utility as a marker for lymph node metastasis in gastric cancer.
Z05252
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
EPHA5 (Ala26-Pro573)
Accession # P54756-1		 His
N-term C-term
Purity > 95% as determined by Bis-­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Loaded EPHA5, His, Human on Anti­-His­-Biosensor can bind Anti­-EPHA5 Antibody, hFc Tag in BLI assay (Gator® Prime). Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 61.9 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 68-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • EPHA5, His, Human
    • EPHA5, His, Human

    The purity of EPHA5, His, Human is greater than 95% as determined by SEC-HPLC.

  • EPHA5, His, Human
    • EPHA5, His, Human

    EPHA5, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Ephrin type-A receptor 5 (EphA5) expression was detected in all non-tumor gastric epithelia but was differentially expressed among gastric cancer samples. EphA5 is differentially expressed in gastric cancer. EphA5 may therefore be a potential therapeutic target and may have clinical utility as a marker for lymph node metastasis in gastric cancer.
Synonyms EHK-1; EK7; BSK; EHK1; HEK7; TYRO4; EphA5; Rek7; TYRO4HEK7CEK7

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.